About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT00855647

Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)

To demonstrate that a hypo-fractionated course of radiotherapy (ie. an accelerated radiotherapy course where fewer but larger doses of radiotherapy are given) is both safe and effective in the treatme...

Lead sponsor: Stanford University•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Stanford University

Age

18 - No limit years

Sex

MALE

Healthy Volunteers

No

Inclusion Criteria

•Patients who have had any form of prior curative treatment (surgery, radiotherapy, cryotherapy) will not be eligible. A prior course of hormone therapy of less than 3 months duration will be allowed.
•Adult men will be considered.
•No life expectancy restrictions will apply.
•Performance Status will not be considered.
•No requirements for organ or marrow function will be made

Exclusion Criteria

•The use of other concurrent Investigational Agents will not be allowed.
•No exclusion requirements due to co-morbid disease or incurrent illness.
•No requirements regarding history of allergic reactions.
•Pregnancy or nursing patients is not applicable (ie. patients are male).

Related studies

Low to Moderate Load Power Training for Men With Metastatic Prostate Cancer.

NCT07572760 · Prostatic Neoplasms

RECRUITINGPhase 1/2

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

NCT06190899 · mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, and more

RECRUITINGPhase 3

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07225946 · Prostatic Neoplasms, Castration-Resistant

RECRUITINGPhase 1/2

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

NCT04868604 · Prostatic Neoplasms, Castration-Resistant

Prostate Adaptive Radiation Therapy

NCT06547398 · Prostatic Neoplasms

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 3, 2010Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment99,999

Start dateAug 2003

Last updatedJun 3, 2010

Condition

Prostatic Neoplasms

Locations shown

Stanford University School of Medicine

Stanford, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 3, 2010Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions